Down 61% From Record Highs, Can Well Health Stock Recover in 2024?

Well Health has crushed broader market returns since its IPO and continues to trade at a discount to consensus price target estimates.

| More on:

Shares of Canada-based health-tech company Well Health (TSX:WELL) have taken investors on a roller-coaster ride since its IPO (initial public offering) in May 2016. The TSX stock surged from $0.15 in May 2016 to a record high of $8.7 in July 2021. Today, Well Health stock trades at $3.6, which is 61% below all-time highs.

Despite its pullback, Well Health has returned a monstrous 3,490% to shareholders, easily outpacing the broader markets. Let’s see if the growth stock can recover and reclaim all-time highs in 2024.

Is Well Health stock a good buy right now?

Valued at $881 million by market cap, Well Health aims to disrupt legacy healthcare services in Canada and the United States. It offers omnichannel patient services delivered at scale via a network of primary, secondary, and integrated care facilities. Well Health operates the largest outpatient medical clinic network in Canada while providing virtual services such as telehealth, ePharmacy, digital bookings, workflow automation, revenue cycle management, and more.

Over the years, Well Health has aggressively acquired companies, allowing it to increase revenue from $50 million in 2020 to $776 million in 2023. Earlier this month, Well Health Clinic Network, a subsidiary of Well Health, entered an agreement with Shoppers Drug Mart to acquire all primary care medical clinics under the Health Clinic by Shoppers brand. The acquisition includes 10 clinics and four physicians, which should contribute $8 million in annual sales.

Moreover, Well Health aims to enhance operational and service capabilities across the newly added clinics while optimizing cost structure, integrating digital workflows, adding patient engagement technologies, and implementing AI (artificial intelligence) tools and capabilities.

How did Well Health perform in Q4 of 2023?

Well Health ended 2023 with record sales, adjusted EBITDA (earnings before interest, tax, depreciation, and amortization), net income, and patient visits. While organic growth stood at 15% for the company in 2023, acquisition-adjusted revenue growth was much higher at 36%, as Well Health continues to attract clinics to its network.

Well Health reported revenue of $231.2 million in the fourth quarter (Q4) of 2023, an increase of 48% year over year, compared to sales of $156.5 million in the year-ago period. Well Health attributed the growth to acquisitions, seasonally strong patient visits in primary care, and healthy organic growth in the virtual services segment. The company recorded 1.2 million patient visits in Q4, up 30% year over year.

In 2024, Well Health is focused on improving profitability and capital efficiency. It aims to end the year with revenue of close to $1 billion and adjusted EBITDA of between $125 million and $130 million. Further, Well Health emphasized that it would reduce capital allocation towards mergers and acquisitions and prioritize organic growth, given its growing attractiveness to care providers in Canada and the U.S.

Is Well Health stock undervalued?

Analysts tracking Well Health expect sales to rise by 23% to $956 million in 2024 and by 9.7% to $1.05 billion in 2025. Comparatively, its bottom line is forecast to improve from a loss per share of $0.03 in 2024 to earnings per share of $0.17 in 2025.

So, priced at less than one times forward sales, WELL stock is quite cheap and trades at a discount of 110% to consensus price target estimates.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Tech Stocks

Rocket lift off through the clouds
Tech Stocks

2 Growth Stocks That Could Skyrocket in 2025 and Beyond

Wondering what types of stocks could rapidly rise in 2025? Check out these two stocks with substantial upside if they…

Read more »

up arrow on wooden blocks
Tech Stocks

The 3 Smartest Tech Stocks to Buy With $500 Right Now

Tech stocks can be seen as a bit risky, but these three have far less risk and more stability for…

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Tech Stocks

Shopify: A Must-Have Growth Stock for Your TFSA Now (and the Next 10 Years)

Shopify (TSX:SHOP) stock isn't just a top growth company, it's a titan worth owning in your decades-long TFSA fund.

Read more »

cloud computing
Tech Stocks

Best Stock to Buy Right Now: Manulife vs CIBC

Want the best stocks? These two are certainly the best options. But which is the better buy?

Read more »

profit rises over time
Tech Stocks

4 Reasons to Buy Constellation Software Stock Like There’s No Tomorrow

Constellation Software stock continued its climb upwards after recent earnings, and this only adds to its appeal.

Read more »

calculate and analyze stock
Tech Stocks

1 Stock That’s Just as Hot as Nvidia (Without All the Hype)

Nvidia stock may look like a strong option, but its valuation is through the roof. Enter this other under-the-radar stock.

Read more »

A plant grows from coins.
Tech Stocks

3 Growth Stocks Wall Street Might Be Sleeping on, But I’m Not

Don’t miss your chance to load up on these three beaten-down stocks.

Read more »

think thought consider
Tech Stocks

Is CGI Stock a Buy Even With No Dividend Yield?

CGI stock may not have a dividend to speak of. But does that necessarily mean you should ignore this top…

Read more »